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mission indicated mortality with excellent performance. C5-expression on day 1 after trauma correlated
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Abstract
Introduction: Severe trauma triggers a systemic inflammatory response that contributes to secondary complications,
such as nosocomial infections, sepsis or multi-organ failure. The present study was aimed to identify markers predicting
complications and an adverse outcome of severely injured patients by an integrated clinico-transcriptomic approach.
Methods: In a prospective study, RNA samples from circulating leukocytes from severely injured patients
(injury severity score ≥ 17 points; n = 104) admitted to a Level I Trauma Center were analyzed for dynamic
changes in gene expression over a period of 21 days by quantitative RT-PCR. Transcriptomic candidates were
selected based on whole genome screening of a representative discovery set (n = 10 patients) or known mechanisms
of the immune response, including mediators of inflammation (IL-8, IL-10, TNF-α, MIF, C5, CD59, SPHK1),
danger signaling (HMGB1, TLR2, CD14, IL-33, IL-1RL1), and components of the heme degradation pathway
(HP, CD163, HMOX1, BLVRA, BLVRB). Clinical markers comprised standard physiological and laboratory parameters and
scoring systems routinely determined in trauma patients.
Results: Leukocytes, thrombocytes and the expression of sphingosine kinase-1 (SPHK1), complement C5, and
haptoglobin (HP) have been identified as markers with the best performance. Leukocytes showed a biphasic
course with peaks on day 0 and day 11 after trauma, and patients with sepsis exhibited significantly higher
leukocyte levels. Thrombocyte numbers showed a typical profile with initial thrombopenia and robust thrombocytosis
in week 3 after trauma, ranging 2- to 3-fold above the upper normal value. ‘Relative thrombocytopenia’ was associated
with multi-organ dysfunction, the development of sepsis, and mortality, the latter of which could be predicted within
3 days prior to the time point of death. SPHK1 expression at the day of admission indicated mortality with excellent
performance. C5-expression on day 1 after trauma correlated with an increased risk for the development of nosocomial
infections during the later course, while HP was found to be a marker for the development of sepsis.
Conclusions: The combination of clinical and transcriptomic markers improves the prognostic performance and may
represent a useful tool for individual risk stratification in trauma patients.
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Introduction
The acute inflammatory response is organized within a
highly complex “network of inflammation” [1], which is
carefully orchestrated under regular conditions and is re-
quired for post-injury regeneration and tissue repair.
However, in the case of an overwhelming initial insult
loss or failure of control, mechanisms can lead to
systemic inflammation with additional harm to host cells
and organs, eventually resulting in multiorgan failure
(MOF) [2, 3]. Based on previous research, different
models for the inflammatory response following major
trauma have been conceptualized, all of which have in
common that the underlying pathophysiology and mo-
lecular mechanisms of the host response are responsible
for adverse events and a complicated recovery [4–8].
The pathophysiology of systemic inflammation is thus
taken into account in contemporary treatment concepts,
such as damage control surgery [9–12]. However, specific
immune modulatory therapies for the treatment of
severely injured trauma patients and septic patients could
not be established to date. Furthermore, clinical decision-
making is still based on general, unspecific physiologic
parameters and the physicians’ experience. Despite exten-
sive research in the past, only C-reactive protein (CRP),
procalcitonin (PCT), and—to a lesser extent—interleukin
(IL)-6 found their way into routine clinical use for assess-
ment of the immune response in trauma-induced systemic
inflammation and sepsis [12, 13].
Initial research focused on detection of circulating
mediators of inflammation that are released upon severe
trauma, and the initial inflammatory response was com-
monly referred to as a “cytokine storm” [14]. Meanwhile,
it has become evident that the host response comprises
complex interactions between inflammatory, humoral,
neurological, and endocrine systems [1, 9]. This is
reflected by novel approaches for a better understanding
of the pathophysiology, including large-scale genomic,
proteomic, and cellular immune signatures [5, 15, 16]. In
contrast to previous studies which focused on the role of
individual mediators and mechanisms, new research di-
rections aim for a systemic perspective at the proteomic
level as well as the genomic level. These recent studies
revealed the complexity of the transcriptomic events
underlying inflammation, but the applicability of this
information in the clinical setting is still limited. We pos-
tulated that by combining gene expression changes with
routinely used clinical and laboratory parameters it would
be possible to improve the prognostic performance.
On the one hand, candidate genes were selected based
on previous knowledge of their role in the pathophysiology
in systemic inflammation, including danger-associated
molecular patterns (high mobility group box protein-1
(HMGB1) [17, 18], IL-33 [19, 20]), interleukin-1 receptor-
like 1 (IL-1RL1, ST2) [19, 20], components of the
complement system (C5) [21, 22], sphingosine kinase
(SPHK)-1 [23, 24], and selected cytokines (tumor necrosis
factor alpha (TNFα) [25, 26], macrophage migration inhibi-
tory factor (MIF) [27–29], IL-8 [30], IL-10 [31]). On the
other hand, candidate selection was based on whole
genome analyses of a representative discovery set, which
comprised genes of the pathogen-recognition receptors
(toll-like receptor (TLR) 2); CD14) and the complement
system (CD59), as well as members of the heme degrad-
ation pathway (haptoglobin (HP), CD163, heme
oxygenase-1 (HMOX1), biliverdin reductase (BLVR) A and
B). With this approach we could show that the
combination of clinical and transcriptomic markers
(clinico-transcriptomic analyses) improves the prognostic
performance and may represent a useful tool for individual
risk stratification in trauma patients.
Materials and methods
Study design
Blood was sampled from 104 patients with multisystem
trauma admitted to the Division of Trauma Surgery
(level I trauma center) at the University Hospital Zurich
from December 2009 to March 2012. Criteria for study
enrollment included patient age ≥18 years, an Injury
Severity Score (ISS) ≥17 points, and time from injury to
admission <6 hours. All patients were recruited into the
study under informed consent guidelines approved by
the Cantonal Ethic Commission Zurich (StV 26-2007)
and international ethical guidelines (ClinicalTrials.gov:
NCT02508272). Study subjects were treated under the
guidance of standard operating procedures developed
and implemented at the University Hospital Zurich
(based on guidelines of the German Society of Trauma
(DGU) [32]). Whole blood from trauma patients was
collected within the first 6 hours after trauma (day 0)
and on days 1, 2, 3, 5, 7, 10, 14, and 21. Clinical out-
comes and complications within 28 days after injury
were recorded. To illustrate the underlying study design,
a CONSORT flow diagram is displayed in Fig. 1. The
total cohort consists of 104 trauma patients. For analysis
of clinical and laboratory parameters, all 104 patients
were included. Ten of 104 patients, with unambiguous
clinical presentation with respect to the development of
sepsis or systemic inflammation without infection, were
selected as a representative discovery set (n = 10 patients;
n = 90 samples) which was analyzed by whole genome
screening in a recent study [GEO:GSE70311]. Candidate
genes were identified by standard statistical methods for
analysis of microarray datasets: gene set enrichment ana-
lysis (GSEA) was performed using hypergeometric tests
with FDR correction within the GeneAnswers, https://
www.bioconductor.org/ package mapped to Reactome
pathways and Gene Ontology (GO) categories. Further stat-
istical procedures comprised explorative gene set analysis
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and principle component analysis. After candidate
gene selection and exclusion of patients with de-
graded or missing samples at intermediate time
points, candidate genes were validated in the total co-
hort (n = 71 patients; n = 517 samples) by quantitative
RT-PCR. The rates of adverse outcomes for either
group are indicated in Table 1.
Clinical data
Clinical data were collected daily in a prospective manner.
The occurrence and severity of systemic inflammation,
sepsis, MOF, and nosocomial infections were retrospect-
ively analyzed using the corresponding clinical parameters
and scores from patients’ records. Systemic inflammation
was defined according to criteria of the American College
of Chest Physicians/Society of Critical Care Medicine
Consensus Conference [2, 33]. For assessment of the
severity of trauma-induced systemic inflammation a scor-
ing system was used (Additional file 1: Table S1) [34].
Based on this Systemic Inflammation score (SI score),
secondary sepsis in trauma patients was defined as ΔSI
score (difference of SI score between two consecutive time
points) ≥ +2 points in concomitance with an infectious
focus or positive blood cultures. MOF was defined accord-
ing to the Sequential Organ Failure Assessment (SOFA)
score [35].
RNA isolation
PaxGene (PreAnalytix, Hombrechtikon, Switzerland)
tubes were used for sampling and preservation of whole
blood, and total cellular RNA from circulating leuko-
cytes was isolated (PaxGene Blood RNA Kit; PreAn-
alytix) in a Qiacube apparatus (Qiacube, Hilden,
Germany) according to the manufacturer’s instructions.
RNA integrity was proven using Experion (Biorad, Mun-
ich, Germany) microcapillary electrophoresis. Samples
exhibiting a RNA quality indicator number (RQI) >7.5
(calculated by Experion System Operation and Data
Analysis Tool; Biorad) were included and processed.
Most of the isolated totRNA samples met these require-
ments, with the exception of four out of 710 samples
(four patients); more than 90 % had RQI >8.5. Some of
the samples contained insufficient RNA concentrations
for reverse transcription. These patients were therefore
excluded from the study (31 samples, n = 16 different
Fig. 1 CONSORT flow diagram of the study design. qRT-PCR quantitative RT-PCR, w/o without
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patients). An additional three patients were excluded
because of missing samples at early or intermediate time
points. In total, 23 patients were excluded from the
analyses. For cDNA synthesis, 1 μg total RNA/sample
were transcribed (RevertAid First Strand cDNA Synthesis;
ThermoFisher Scientific, Schwerte, Germany; and PTC-
200 Thermal Cycler Dual; BioRad) according to the man-
ufacturer’s protocol. Only patients with missing or de-
graded total RNA samples at intermediate time points
(before the end of the observation period, or prior to dis-
charge or death of the patient), resulting in discontinuous
sampling, were excluded. After quality control and exclu-
sion of degraded samples, patients completely unimpaired
RNA sample sets at all time points (n = 71 patients) were
subjected to quantitative RT-PCR.
Quantitative RT-PCR
Quantitative RT-PCR was performed in a two-step
protocol using the Rotor-Gene system and Rotor-Gene
SYBR Green PCR Kit (Qiagen, Hombrechtikon,
Switzerland) according to the manufacturer’s information
with 250 nM Primer mix and 25 ng cDNA. Initial
denaturation was at 95 °C for 5 minutes, followed by 50 -
cycles of denaturation at 95 °C for 5 seconds and anneal-
ing/extension at a given temperature (see Additional file 2:
Table S2) for 15 seconds, finally followed by a melting
curve. Cycle threshold (CT) values and efficiency were doc-
umented for each sample, and data were normalized using
the housekeeping gene ACTB:
ΔCT ¼ CT ACTB½ –CT Candidate½ :
Primers were purchased from Biomers (Ulm,
Germany). The primer sequences are listed in Additional
file 2: Table S2.
Statistical analysis
Comparisons of ΔCT values for the various groups were
displayed in box-whisker plots. Significance was attained
at p <0.05 using the Mann–Whitney U (Wilcoxon rank
sum) test. Similarity was assessed using parametric (r)
and nonparametric (ρ) measures. Differences in time
courses were assessed by two-way analysis of variance
(ANOVA). A bivariate greedy search algorithm was
applied for identification and ranking of the best candi-
dates regarding their performance, which was further
characterized by receiver operating characteristic (ROC)
curve analysis. Analyses were performed using R
software version 3.1.1 (http://www.r-project.org/) and
GraphPad Prism 5 (GraphPad Software Inc., La Jolla,
Table 1 Patient characteristics
Parameter Total cohort (n = 104) PCR cohort (n = 71)
Demographics
Age (years) 43.5 ± 1.77; 42 (18–92) 41.6 ± 2.0; 40 (18–80)
Sex (male/female) 77/27 52/19
Glasgow Coma Scale 11.9 ± 0.41; 14 (3–15) 11.9 ± 0.5; 14 (3–5)
Injury Severity Score 32.8 ± 1.3; 31 (17–75) 31 ± 1.5; 29 (13–75)
SOFA score initial 4.8 ± 0.3; 5 (0–12) 4.19 ± 0.4; 4 (0–12)
SOFA score maximum 7.7 ± 0.4; 8 (0–18) 6.9 ± 0.5; 7 (0–18)
Outcomes
RISC (% survival) 83.3 ± 2.5 85 ± 2.8; 96.3 (9.8–98.9)
Survival 88 % (13 nonsurvivors) 90 % (7 nonsurvivors)
Hospital length of stay (days) 26.6 ± 1.8; 21.5 (2–119) 25 ± 2.1; 20 (3–119)
Intensive care unit length of stay (days) 13.9 ± 1.4; 10 (2–86) 11.2 ± 1.2; 8 (2–47)
Allogenic blood transfusion
TASH score (points) 8.5 ± 0.6; 8 (0–23) 7.8 ± 0.7; 7 (0–23)
TASH (%) 13.9 ± 2.0 12.4 ± 2.2; 5 (5–82)
Initial (day 0) pRBC transfusion (units) 4.0 ± 0.8; 1 (0–54) 3.1 ± 0.7; 0 (0–28)
Total pRBC transfusion 9.6 ± 1.3; 5 (0–70) 7.8 ± 1.2; 4 (0–58)
Infectious complications
Nosocomial infections 56/104 (53.9 %) 34/71 (48 %)
Sepsis 15/104 (14.0 %) 10/71 (14.1 %)
Data presented as mean ± standard error of the mean; median (minimum–maximum)
SOFA Sequential Organ Failure Assessment, pRBC Packed Red Blood Cells, RISC Revised Injury Severity Classification Score, TASH score Trauma Associated Severe
Hemorrhage Score
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CA, USA). Multivariate analyses, including ANOVA,
multivariate linear models with post hoc-corrected p
values, and lagged correlation analyses of various clinical
parameters (leukocytes, platelets, sepsis, SI score, time,
mortality, gender, age, etc.) and candidate gene expres-
sion, have been employed. For cluster analysis Fig. 6, time
index of peak measurements were used in order to evalu-
ate and illustrate common features and expression pat-
terns and their temporal relationships in patients with a
similar clinical course and outcome with respect to noso-
comial infections and sepsis. Machine learning was ap-
plied for decision tree generation by 10-fold cross-
validation. Decision trees/candidates were selected upon
high specificity.
Results
Patient population
Characteristics of the patient cohort are presented in
Table 1. A total of 104 trauma patients with an ISS ≥17
points were enrolled in the study. The mean ISS was
32.8 points. The leading injury mechanism was blunt
trauma. Thirteen of 104 patients died within the obser-
vation period of 28 days (mortality rate 12 %). Sepsis
occurred in 15 of 104 patients (14 %). Fifty-six patients
developed nosocomial infections during hospitalization
(54 %), including ventilator-associated pneumonia, surgi-
cal site infections, and urinary tract infections as the
most frequent causes (for time points of sepsis diagnosis
and death (see Additional file 3: Table S3).
Leukocytes reflect the severity of systemic inflammation
and correlate with the development of sepsis, while
thrombocytes are associated with an adverse outcome
in general
After severe trauma, leukocyte and thrombocyte counts
underlie a dynamic regulation that starts immediately
after the initial injury and is affected by multiple condi-
tions, such as consumption during hemorrhagic shock
and coagulopathy, bone marrow activation, or induction
of processes necessary for tissue regeneration and repair.
While the predictive value of leukocyte levels and
thrombocytopenia is well established in sepsis in non-
trauma patients, to our knowledge a systemic longitu-
dinal analysis in trauma is not available. We therefore
first correlated the changes in leukocyte counts during
the course of time. As displayed in Fig. 2a, the severity
of systemic inflammation as assessed by the SI score
correlated with the number of leukocytes in the blood
compartment. Leukocyte counts after severe trauma
showed an early peak at the day of admission (day 0),
followed by a rapid decline on day 1 to values in the
normal range (Fig. 2b). Starting at day 5 after trauma,
leukocyte numbers rose again to a second peak on day
11, and then gradually declined during the further
Fig. 2 Systematic analysis of leukocyte a–d and thrombocyte counts e–h in trauma patients (n = 104 patients). a, e Correlation with the severity of
systemic inflammation (SI score). b, f Time course of the total cohort. c, g Subgroup analysis of patients with or without sepsis as a function of time.
d, h Comparison of time courses of survivors and nonsurvivors. *p <0.05
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course (Fig. 2b). Secondly, we analyzed the changes in
leukocyte counts in groups of patients with respect to
outcomes. Patients with sepsis showed significantly
elevated leukocyte levels, which were particularly
pronounced beyond day 4 (Fig. 2c). However, there
were no significant differences in the leukocyte course
between survivors and nonsurvivors (Fig. 2d).
In contrast to leukocytes, thrombocyte counts did not
reflect the severity of inflammation after trauma (Fig. 2e).
As for their time course, thrombocyte numbers initially
decreased, and beginning on day 4 thrombocyte numbers
continuously rose to a plateau on day 13, followed by an
undulating course afterwards (Fig. 2f). The levels in the
third week after trauma collectively ranged approximately
threefold above the upper normal value (Fig. 2f). In patients
with sepsis, thrombocyte levels were significantly lower, the
increase of thrombocyte numbers was delayed (right shift
of the curve), and the plateau in week 3 ranged at signifi-
cantly lower levels as compared with patients without septic
complications (Fig. 2g). A similar pattern was found for
mortality, with significantly lower thrombocyte levels in
nonsurvivors, suggesting that inadequate increase of
thrombocyte numbers after severe trauma is associated with
an adverse outcome or with septic complications (Fig. 2h).
Performance of leukocytes, thrombocytes, and their
combination as markers for outcome of trauma patients
Based on the previous results, prognostic performance
of leukocytes and thrombocyte counts and their combin-
ation was assessed and compared with the routinely
used parameter PCT. Thrombocyte counts showed a
performance for mortality in trauma patients with
slightly better area under the curve (AUC) values (AUC=
0.76) than PCT (AUC= 0.75), which could be improved
when combined with leukocyte counts (AUC thrombo-
cytes/leukocytes = 0.8; Fig. 3a). In relation to the time point
of death, thrombocyte/leukocyte levels determined 2 days
prior to the event still performed with an AUC value of
0.73 (Fig. 3a). With regard to clinical applicability, the
performance of thrombocytes and leukocytes was evaluated
within a period of 3 days prior to the time point of death.
In this setting, thrombocytes and leukocytes were found
to be reliable markers to predict a lethal outcome
(AUC thrombocytes = 0.73; AUC thrombocytes/leukocytes
= 0.75); with increasing performance, the intervals between
sampling and the lethal event were shorter (Fig. 3b).
Cluster analysis of selected transcriptomic candidates
With the goal of stratifying the importance of the se-
lected genes, an unsupervised clustering was conducted
of all selected transcriptomic markers. Expression was
adjusted to the housekeeping gene ACTB and to baseline
levels (day 0; ΔΔCT). As shown in Fig. 4a, HP and
CD163 of the heme degradation pathway clustered
together, and C5 grouped with BLVRB, while HMOX1
clustered with candidates of the pathogen recognition
receptor family (TLR2, CD14) and cytokines (TNFα).
Another cluster comprised the DAMP HMGB1, the
cytokine MIF, and SPHK1 (Fig. 4a).
Expression of the top transcriptomic performers C5, HP,
and SPHK1 as markers for infectious complications, sepsis,
or mortality
We further tested for potential correlations between our
candidate genes and clinical outcomes. The expression of
C5 (ΔCT) showed only a weak negative correlation with
Fig. 3 a ROC curves for thrombocytes (Tc), leukocytes (Lc), the combination of the two (Tc/Lc), and PCT as “positive control” regarding the outcome
(mortality). b ROC curve analysis (mortality) for Tc, Tc/Lc, and PCT within 3 days prior to the time point of death. Area under the curve (AUC) values
are provided
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the severity of disease (SI score; Fig. 4b). However, C5
expression on day 1 after trauma was significantly lower
in patients who developed nosocomial infections during
the further course than those without infectious
complications (Fig. 4c), with moderate sensitivity/specificity
(AUC= 0.68; Fig. 4d).
In a previous study describing the role of the heme deg-
radation pathway in the development of secondary sepsis
in severely injured patients, HP expression in circulating
leukocytes reflected the severity of systemic inflammation,
and, most importantly, significant upregulation was found
in trauma patients with sepsis. In line with these findings,
HP was found to be a valid marker for identification of
septic complications in trauma patients in the present
study (Fig. 4e, AUC = 0.72).
Regarding the expression of SPHK1, no correlation
with the SI score was found (Fig. 4f ). Strikingly, SPHK1
expression was significantly lower in nonsurvivors than
in survivors as early as at the time point of admission to
the emergency department (day 0; Fig. 4g). With these
profound differences, all nonsurvivors in the cohort
of the present study ranged below a threshold of
ΔCT ≤ –10 (Fig. 4g). In accord, ROC analysis revealed
an outstanding performance for SPHK1 expression on
day 0 regarding mortality (Fig. 4h; AUC = 0.89).
Comparison of performance of individual markers
Performances of each single marker (leukocytes, throm-
bocytes, C5, HP, SPHK1, and the routinely used labora-
tory parameters CRP and PCT) were compared with
respect to various outcomes (sepsis, nosocomial infec-
tions, mortality) and time points of assessment (day 0,
day 1, all days; Fig. 5). As the main results, PCT was
found to be a reliable marker for prediction of sepsis
and mortality at early time points (day 0, day 1), while
HP was the best marker for sepsis when all time points
were considered. In accordance with Fig. 4h, SPHK1
showed the best performance among all single markers
for mortality on day 0 (Fig. 5).
Temporal relationship of clinical and transcriptomic
candidates
Hierarchical cluster analysis of various clinical and
transcriptomic markers using time index of peak
Fig. 4 Characterization of selected transcriptomic markers with best performance. a Dendrogram depicting unsupervised cluster analysis of all
transcriptomic markers: HP, CD163, HMOX1, BLVRA, BLVRB, IL-10, TLR2, CD14, IL-8, HMGB1, IL-33, IL-1RL1, C5, CD59, TNFα, MIF, SPHK1, HPRT, TUBB,
and ACTB. b Correlation of C5 expression (ΔCT) with the systemic inflammation (SI) score (n ≥ 53 patients). c Expression of C5 in leukocytes on
day 1 after trauma from patients who developed nosocomial infections during the further course in comparison with patients without infection.
ROC curves for d C5 (endpoint: nosocomial infection; AUC = 0.68) and e HP (endpoint: sepsis; AUC = 0.71). f Correlation of SPHK1 expression (ΔCT)
with the SI score (n = 71 patients). g Comparison of SPHK1 expression (ΔCT) in survivors and nonsurvivors. h ROC curve for SPHK1 on day 0 (endpoint:
mortality; AUC = 0.89). *p <0.05. HP haptoglobin, SPHK sphingosine kinase
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measurements (time after injury to reach maximum
values; Fig. 6) was applied in order to identify and illus-
trate common expression patterns and their temporal re-
lationships in patients with a similar clinical course and
outcome with respect to nosocomial infections and sepsis.
Patients with infectious complications, including sepsis,
showed distinct patterns (Fig. 6, upper left quadrant of
heatmap). In this group, C5 clustered with downstream
components of the heme degradation pathway (BLVR),
thrombocytes, and prothrombin time, suggesting common
regulatory mechanisms. The relationship of these peak dy-
namics is further characterized in Fig. 7 (evaluation of lag
effects and trajectories). The remaining transcriptomic
candidates of the heme degradation pathway (HP, CD163,
HMOX1; IL-10) and IL-8 clustered together, with moder-
ate correlation to nosocomial infections (Fig. 6, lower half
of the heatmap). The figure also implies that there are
inter-individual differences in the dynamics of all markers,
reflecting the heterogeneity of trauma patient cohorts.
Association and causality of C5, thrombocytes, and
prothrombin time
Based on the temporal expression patterns of the cluster
analysis presented in Fig. 6, the association between C5
expression, thrombocyte counts, and routine coagulation
tests (prothrombin time; Fig. 7a–c), all of which may be
affected by or even contribute to trauma-induced coagu-
lopathy, was assessed in further detail. This association
was found to underlie lag effects by 1 day (indicated by
d–1 or d + 1 in Fig. 7a–c), with changes of the pro-
thrombin time preceding the corresponding alterations
of C5 expression or thrombocyte numbers. This associ-
ation was specific for the prothrombin time but not for
the activated partial thromboplastin time (Fig. 7d, e).
However, in the setting of the present study, prothrom-
bin alone failed to be a reliable prognostic marker.
Instead, lagged correlation analysis of C5 and thrombo-
cytes revealed distinct patterns, with which the nonsur-
vivors could be discriminated (Fig. 7f ). Collectively
(Figs. 6 and 7), these analyses reflect the temporal dy-
namics of the systemic inflammatory response after
trauma and provide additional insights as compared with
sole correlation analyses. Distinct temporal patterns of
certain clinical and transcriptomic features may be used
for discrimination of outcomes (e.g., infectious compli-
cations and sepsis).
Decision tree cross-validation
Finally, under consideration of all the longitudinal data
presented, the combined, hierarchical application of
various markers was assessed by decision tree cross-
validation. As displayed in Fig. 8, these analyses revealed
Fig. 5 Comparison of the performance (heatmap of AUC values) of selected clinical and transcriptomic parameters regarding specific outcomes
(sepsis, nosocomial infections (NI), mortality) and time points of assessment (day 0 (d0), day 1 (d1), all days); n = 71 patients. AUC area under the
curve, CRP C-reactive protein, HP haptoglobin, PCT procalcitonin, SPHK sphingosine kinase
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different combinations of markers depending on the
outcome parameter (nosocomial infection; sepsis) and
the time point of assessment (day 1 after trauma vs. all
time points during the observation period). To evaluate
the trauma patients’ risk for developing of nosocomial
infections at any time point, the hierarchical combin-
ation of HP expression (primary level) and thrombocytes
(secondary level) may be used (Fig. 8a; specificity =
0.9097; sensitivity = 0.6154; AUC = 0.7332). Development
of sepsis during the further course is indicated by C5 ex-
pression on day 1 after trauma followed by assessment
of HP expression at the same time point (Fig. 8b; specifi-
city = 0.9565; sensitivity = 0.6250; AUC = 0.7880). When
all time points during the observation period are consid-
ered, the incidence of sepsis can be assessed by measure-
ment of HP expression at a certain time point (primary
level), followed by evaluation of leukocyte counts (sec-
ondary level). Here, leukocyte levels greater than
20.21 g/l are indicative for the development of sepsis.
For patients with leukocyte levels below this threshold,
HP expression can be assessed on the tertiary level for
the risk of sepsis (Fig. 8c; specificity = 0.9657; negative
predictive value = 0.9174; positive predictive value =
0.6428; AUC = 0.8219).
Discussion
In the present study, we sought to identify clinical and
transcriptomic markers (clinico-transcriptomic analysis)
and their combination that correlate with the outcome
and indicate the patients’ risk for adverse outcomes and
for developing secondary complications following trauma,
including nosocomial infections and sepsis. The selection
of transcriptomic markers was based on previous findings
from whole genome analyses and known mechanisms of
the inflammatory response, and comprised various media-
tors of inflammation (cytokines, complement system),
Danger-Associated Molecular Patterns (DAMPs) and Pat-
tern Recognition Receptors (PRRs), and the heme degrad-
ation pathway. Clinical markers included standard
physiological and laboratory parameters and scoring sys-
tems routinely determined in the assessment of trauma
patients. In a recent study by our group, the heme degrad-
ation pathway has been found to be upregulated in trauma
patients who developed sepsis as compared with trauma
patients with an uncomplicated recovery. As mentioned
in the Introduction, several studies with a similar objective
in comparable trauma patient cohorts exist [4, 5, 7, 8].
However, each of these studies, including the present
study, revealed a different set of candidate genes to be
Fig. 6 Hierarchical cluster analysis of various clinical and transcriptomic markers with regard to time index of peak measurements (time after
injury to reach maximum values) in relation to the binary outcome variables nosocomial infection and sepsis. n = 71 patients. aPTT activated
partial thromboplastin time, BLVR Biliverdin reductase, CRP C-reactive protein, HMOX1 heme oxygenase-1, HP haptoglobin, IL interleukin, IL-1RL1
interleukin 1 receptor-like 1, PCT procalcitonin, SI score systemic inflammation score, SOFA Sequential Organ Failure Assessment, TLR toll-like
receptor, GCS Glasgow Coma Score, pRBC Packed Red Blood Cells
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used as markers in trauma patients, with only little over-
lap. This discrepancy may be due to differences in the
study design, different methods applied (different micro-
array platforms vs. NanoString vs. PCR), or nonuniform
classification of clinical conditions (e.g., complicated dis-
covery vs. sepsis). In the present study, we were able to
demonstrate that HP in particular represents a promising
marker for the development of sepsis after trauma, which
precedes the occurrence of clinical signs of sepsis by at
least 1 day. In addition, TLR2 and CD14 were analyzed as
representatives of the pattern-recognition receptors which
represent another system that was upregulated in sepsis
patients of the discovery set as described previously. While
the temporal changes and regulation of TLR2 and CD14
could be confirmed in the cohort of the present study,
these markers were not found to be superior to clinical
parameters and scores with respect to their prognostic
performance. Likewise, transcription of the selected cyto-
kines IL-6, TNFα, IL-10, and IL-8 showed differential
regulation after trauma but was not found to be expedient
to be used as markers for clinical assessment of trauma
patients, in contrast to their protein equivalents. Although
playing a central role in the initiation of the inflammatory
response, the expression of DAMPs, with HMGB1 in par-
ticular, showed only small changes after trauma. In fact,
HMGB1 expression in leukocytes was similar to the
housekeeping genes ACTB or TUBB. These findings are
in striking contrast to the pattern of the circulating
HMGB1 protein in trauma patients, with an early peak
immediately after trauma [17, 18]. This discrepancy be-
tween proteomic and transcriptomic expression patterns
suggests either that preformed HMGB1 is released upon
trauma or that it is predominantly released from cell types
other than circulating leukocytes.
Among the candidates included in the analyses by
“knowledge-based selection”, C5 and SHPK1 expression
appeared to be proper markers to assess the patients’ risk
for adverse outcomes (infectious complications, mortality)
in the early phase (day 0, day 1) after trauma, in
accordance with their central roles in the pathophysiology
in systemic inflammation.
Among all clinical parameters, leukocytes and thrombo-
cytes were found to be the candidates with reasonable per-
formance. As was to be expected, leukocytes were
Fig. 7 Correlational analyses of C5, thrombocytes, and coagulation tests (prothrombin time; activated partial thromboplastin time (aPTT)). Lag
effects are reflected by analysis of preceding (d–1) and consecutive time points (d + 1). Data are presented as box plots of correlation coefficients
r (n ≥53 patients). a Prothrombin time vs. thrombocyte counts. b Prothrombin time vs. C5 expression (ΔCT). c Thrombocyte counts vs. C5 expression (ΔCT).
d aPTT vs. thrombocyte counts. e aPTT vs. C5 expression (ΔCT). f Heatmap for lagged Pearson correlation of C5 (ΔCT) expression and thrombocyte counts
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increased after trauma peaking at the end of the second
week. Leukocyte counts reflected the severity of systemic
inflammation and were significantly elevated in patients
who developed secondary sepsis, but there were no
differences between survivors and nonsurvivors. As for
the thrombocyte profile in trauma patients, significant dif-
ferences were found in patients who developed sepsis or
who did not survive. In both subgroups, a right shift of the
curve occurred, and the typical plateau in the third week
after trauma was reached at significantly lower levels. This
“relative thrombocytopenia” was also associated with mul-
tiorgan dysfunction (SOFA score >8 points). Thrombo-
cytes thus represent an all-round marker for a
“complicated recovery” and adverse outcome, whose dis-
crimination capability and performance may even be im-
proved when combined with other markers. In this
context, it is important to note that not the absolute
values of thrombocyte counts, but the delayed increase
during the first week (right shift) and the lower level of
the plateau during the third week in relation to patients
with an uncomplicated recovery were indicative for ad-
verse events. It is well established that following initial
thrombocytopenia due to consumption, thrombocyte
counts increase after trauma in response to release of
thrombopoietin [36]. In accord with our findings, it has
been suggested that increased thrombocyte levels after
trauma are associated with an improved survival, while
the significance of trauma-associated thrombocytosis
remained unclear [37]. Our findings with detailed analysis
of the kinetics of circulating thrombocytes by daily mea-
surements over a period of 3 weeks suggest that late
thrombocytosis may be required for proper post-injury re-
generation and tissue repair, whereas the early decline
may be due to consumption and trauma-associated coagu-
lopathy. Regarding their functional role, it became evident
that thrombocytes are closely linked to immunity [38]:
thrombocytes are activated by DAMPs and Pathogen-
Associated Molecular Patterns (PAMPs) and express im-
mune receptors on their surface, including complement
receptors and PRRs (TLR) [39, 40]. Inappropriate
Fig. 8 Integrated use of clinical and transcriptomic markers assessed by decision tree cross-validation (10-fold cross-validation; decision
trees/candidates were selected upon high specificity). a Decision tree for the incidence of nosocomial infections after trauma under consideration of all
time points of the observation period (n= 413 samples). b Assessment of the risk for the development of sepsis during the further course using samples
from day 1 after trauma (n= 77 samples). c Decision tree for sepsis under inclusion of all time points of the observation period (n= 502 samples). Threshold
levels (ΔCt of gene expression or leukocyte/thrombocyte counts) for the decision of which path is taken are provided in the figures at the corresponding
levels. C5 complement component C5, HP haptoglobin, Lc leukocytes, Tc thrombocytes
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activation of thrombocytes during systemic inflammation
is a major contributor to disseminated intravascular co-
agulation, which, in turn, causes early thrombocyte con-
sumption that is related to mortality [41].
In this translational study, application of integrated
clinico-transcriptomic analyses was found to be an effective
approach for risk stratification and outcome prediction in
polytrauma patients, which is in line with several recent re-
ports [5, 42, 43]. By systematic statistical dissection of data
from large-scale analyses, we were able to identify a set of
markers with reliable prognostic performance.
Our data suggest that C5 expression might be used as
an early marker (day 1 after trauma) for identification of
trauma patients at risk for the development of nosoco-
mial infections/sepsis. HP was found to be a reliable
marker for the development of secondary sepsis, which
is based on upregulation of the heme degradation path-
way by free heme after allogenic blood transfusion or
release of myoglobin from traumatic tissue damage, as
implied by a most recent study. As another promising
candidate, SPHK1 has been found to be an early marker
for prediction of mortality, with an excellent performance
as early as at the day of admission (AUC= 0.89). Function-
ally, SPHK signaling is known to play a crucial role in the
development, differentiation, activation, and proliferation
of immune cells [44, 45], and its product sphingosine-1
phosphate has been shown to attenuate multiple organ
dysfunction in an experimental model of trauma/
hemorrhagic shock [46]. In comparison with the perform-
ance of each single marker alone (Fig. 5), these data imply
that in combination the sensitivity and specificity of the
markers can be improved. Another advantage for
inclusion of transcriptomic markers in the assessment of
trauma patients is that changes in the transcription occur
earlier than changes of clinical parameters and scores, and
precede the clinical event (e.g., sepsis). In the case of C5
and SPHK1, differences in patients were even evident as
early as on day 0 (SHPK1) and day 1 (C5) after trauma,
allowing early and timely identification of patients at risk
for infectious complications and an adverse outcome.
From a pathophysiological point of view, the markers
identified by the present study are not only complemen-
tary to each other regarding their prognostic perform-
ance but are also functionally related. A previous study
[47] demonstrated that systemic complement activation
already occurs minutes after severe trauma. Due to its
close interaction with the coagulation cascade [48, 49],
complement activation may thereby contribute to
traumatic coagulopathy. This is reflected by impaired
prothrombin times, which have been described previously
to predict an unfavorable outcome [50]. Trauma-induced
coagulopathy is also hallmarked by early thrombocyte
dysfunction. In our study, thrombocyte counts and C5
expression were linked through the prothrombin time,
and lagged correlations of both markers showed a distinct
pattern in those trauma patients who did not survive.
Thrombocyte-derived microvesicles trigger the upregula-
tion of SPHK1 in monocytic cells in inflammation and
sepsis [51]. Moreover, SPHK-1 can be activated by and
regulates signaling through C5a receptors [52, 53], which
also play central roles in the initiation and progression of
inflammation in sepsis [22].
In summary, our findings indicate that integration of
clinical and transcriptomic markers allows risk stratifica-
tion and prediction of infectious complications and an
adverse outcome in trauma patients. In the cohort of the
present study, leukocytes, thrombocytes, and the expres-
sion of SPHK1, C5, and HP in leukocytes have been
identified as markers with the best performance which
might be used for assessment of trauma patients.
A hypothetical algorithm of how the information from
the present study might be transferred to the clinical
setting is as follows: on the day of trauma (day 0), patients
with a high risk of mortality could be identified by SPHK1
expression, and these patients may be monitored by com-
bined assessment of C5 expression and thrombocyte count
during the further course. The expression of C5 1 day after
trauma (day 1) may indicate the patients’ risk for nosoco-
mial infections and sepsis. In this subgroup, the risk to de-
velop secondary sepsis could further be assessed by HP
expression. In combination with HP expression, leukocyte
levels may help stratify the patients’ risk for development
of sepsis at any time point during the course after trauma.
Conclusions
The integrated application of clinical and transcriptomic
markers (clinico-transcriptomic analyses) improves the
prognostic performance in trauma patients and may
represent a useful tool for individual risk profiling and
stratification. The clinical practicability of this approach
needs to be validated in future prospective studies in
independent trauma patient cohorts.
Key messages
 Expression changes of C5, HP, and SPHK1 in whole
blood from trauma patients have been identified as
markers for infectious complications, sepsis, or
mortality, respectively.
 Leukocyte counts after trauma reflect the severity of
systemic inflammation and correlate with the
development of sepsis, while thrombocyte counts
are associated with adverse outcomes in severely
injured patients.
 The integrated use of clinical and transcriptomic
markers improves the prognostic performance and
may represent a useful tool for individual risk
stratification in trauma patients.
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